Anti-Fibrotic Effect of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells on Skeletal Muscle Cells, Mediated by Secretion of MMP-1

Alee Choi 1,2, Sang Eon Park 1,2,*, Jang Bin Jeong 1,2, Suk-joo Choi 3, Soo-young Oh 3, Gyu Ha Ryu 4,5, Jeehun Lee 6, Hong Bae Jeon 1,*, and Jong Wook Chang 1,2,*

1 Stem Cell Institute, ENCell Co. Ltd., Seoul 06072, Korea; ari0621@encellinc.com (A.C.); earnie.park@encellinc.com (S.E.P.); jb.jeong@encellinc.com (J.B.J.)
2 Stem Cell & Regenerative Medicine Institute, Samsung Medical Center, Seoul 06351, Korea
3 Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul 06351, Korea; drmaxmix.choi@samsung.com (S.-j.C.); ohsymd.oh@samsung.com (S.-y.O.)
4 Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; gyuha.ryu@samsung.com
5 The Office of R&D Strategy & Planning, Samsung Medical Center, Seoul 06351, Korea
6 Department of Pediatrics, Samsung Medical Center, Seoul 06351, Korea; leejeehunmd@gmail.com

* Correspondence: jhb@encellinc.com (H.B.J.); jwchang@encellinc.com or jongwook.chang@samsung.com (J.W.C.); Tel.: +82-2-6205-8055 (H.B.J.); +82-2-3410-6048 (J.W.C.)

Received: 13 August 2020; Accepted: 28 August 2020; Published: 29 August 2020

Abstract: Extracellular matrix (ECM) components play an important role in maintaining skeletal muscle function, but excessive accumulation of ECM components interferes with skeletal muscle regeneration after injury, eventually inducing fibrosis. Increased oxidative stress level caused by dystrophin deficiency is a key factor in fibrosis in Duchenne muscular dystrophy (DMD) patients. Mesenchymal stem cells (MSCs) are considered a promising therapeutic agent for various diseases involving fibrosis. In particular, the paracrine factors secreted by MSCs play an important role in the therapeutic effects of MSCs. In this study, we investigated the effects of MSCs on skeletal muscle fibrosis. In 2–5-month-old mdx mice intravenously injected with $1 \times 10^5$ Wharton’s jelly (WJ)-derived MSCs (WJ-MSCs), fibrosis intensity and accumulation of calcium/necrotic fibers were significantly decreased. To elucidate the mechanism of this effect, we verified the effect of WJ-MSCs in a hydrogen peroxide-induced fibrosis myotubes model. In addition, we demonstrated that matrix metalloproteinase-1 (MMP-1), a paracrine factor, is critical for this anti-fibrotic effect of WJ-MSCs. These findings demonstrate that WJ-MSCs exert anti-fibrotic effects against skeletal muscle fibrosis, primarily via MMP-1, indicating a novel target for the treatment of muscle diseases, such as DMD.

Keywords: Duchenne muscular dystrophy; matrix metalloproteinase-1; paracrine factor; skeletal muscle fibrosis; Wharton’s jelly-derived mesenchymal stem cell

1. Introduction

Skeletal muscle fibrosis, one of the typical symptoms of Duchenne muscular dystrophy (DMD), is an abnormal accumulation of extracellular matrix (ECM) components in muscle tissue and is particularly observed in patients with the end-stage of DMD [1,2]. In fibrotic skeletal muscle, the expression level of pro-fibrotic factors is increased, resulting in excessive deposition of ECM proteins, such as fibronectin. As a result, muscle function is impaired and the regeneration ability of skeletal muscle is diminished, which leads to muscle dysfunction [3–5]. Thus, this pathological symptom is considered a hallmark of muscular dystrophies.
Various studies have investigated the mechanisms underlying skeletal muscle fibrosis and have identified several factors that affect fibrosis, such as oxidative stress, inflammation, and aging [1,6,7]. In particular, oxidative stress in DMD, which is mainly caused by dystrophin deficiency, is considered to be one of the major causes of muscle fibrosis [8,9]. Therefore, alleviation of oxidative stress-induced fibrosis is important in relieving the pathologic condition in patients with DMD. There are several approaches to resolving fibrosis in patients with DMD, but no effective treatment has been developed to date [10].

Currently, numerous clinical trials have proven that mesenchymal stem cells (MSCs) are effective and safe for use in the treatment of various diseases [11–14]. Since MSCs derived from bone marrow, umbilical cord, or adipose tissues are adult stem cells, there are no safety or ethical issues involved [15,16]. Moreover, it is known that various proteins secreted from mesenchymal stem cells, i.e., paracrine factors, have therapeutic potentials [17–19]. The paracrine factors secreted by MSCs help to maintain homeostasis through the regulation of inflammation and the immune systems at the lesion site [20]. Recently, various paracrine factors have been investigated and related studies have suggested that these factors play a pivotal role in the therapeutic effects of MSCs [21–23]. It has been suggested that Wharton’s jelly (WJ)-MSCs, which exert anti-apoptotic, anti-inflammatory, and immunomodulatory effects by secreting paracrine factors, could be an effective therapeutic agent for muscle diseases [24–26]. We have previously demonstrated that WJ-MSCs exert anti-apoptotic effects on skeletal muscle cells under starvation condition, by the secretion of XCL1 protein [27]. However, to date, no study has investigated the effect of WJ-MSCs on fibrosis in patients with DMD.

Therefore, in this study, we investigated whether MSCs attenuate skeletal muscle fibrosis in an mdx animal model. To figure out the mechanisms involved in anti-fibrotic effects of WJ-MSCs, we established a hydrogen peroxide-induced fibrosis model in an in-vitro system. Furthermore, we identified matrix metalloproteinase-1 (MMP-1) as the key paracrine factor that mediates anti-fibrotic effect.

2. Results

2.1. Anti-Fibrotic Effects of WJ-MSCs on an Mdx Model

The effects of WJ-MSCs on DMD pathology were evaluated in the gastrocnemius muscles of an mdx murine model. The level of fibrosis, presenting as the relative area stained with Sirius red solution, was increased in the mdx group as compared to the control group (Figure 1a, 514 ± 5% of the control group value). Additionally, accumulation of calcium/necrotic fibers was increased in the mdx group as compared to the control group (Figure 1b, 661 ± 68% of the control value).

In mdx mice intravenously (I.V) injected with WJ-MSCs, the severity of fibrosis and accumulation of calcium/necrotic fibers was decreased (Figure 1, 280 ± 5% of control value and 265 ± 28% of the control value, respectively). These data imply that WJ-MSCs have a positive effect on degenerative phenotypes of mdx mice.
2.2. Effects of WJ-MSCs on an In-Vitro H2O2-Induced Fibrosis Model

To investigate the role of WJ-MSCs on the fibrosis observed in mdx mice, we established an in-vitro skeletal muscle fibrosis model. There are many possible hypotheses about the cause of fibrosis in DMD, such as aging, trauma, or inflammation [4], but reactive oxygen species (ROS)-induced oxidative stress is considered as a major cause of this feature of DMD. To achieve oxidative stress-induced fibrosis, hydrogen peroxide (H2O2) of various concentrations were used to treat myotubes. We found that...
2 mM H$_2$O$_2$ did not induce cell death of myotubes, but induced fibrosis phenotypes in the treated cells as compared to control cells (Figures A1 and A2). Myotubes treated with 2 mM H$_2$O$_2$ showed damage (Figure 2a), and the area stained with Sirius red solution was increased as compared to the control group (Figure 2b, 133 ± 5% of control group value), indicating fibrotic degeneration. Similarly, the expression level of fibronectin protein, a major ECM protein, was increased in the treated group as compared to the control group (Figure 2c,d, 120 ± 5% of control group value). Along with this change, relative expression levels of myosin heavy chain (MHC), a myotube marker, was decreased in the treated group (Figure 2c and e, 57 ± 8% of control group value). To determine the effect of WJ-MSCs on an H$_2$O$_2$-induced fibrosis model, WJ-MSCs (1 × 10$^5$ cells) were co-cultured with myotubes treated with H$_2$O$_2$. WJ-MSC co-cultures showed attenuated fibrosis. Western blotting analysis showed significantly decreased fibronectin (Figure 2d, 78 ± 14% of control group value) and increased MHC (Figure 2e, 73 ± 9% of control group value) levels in myotubes after co-culturing with WJ-MSCs. These data demonstrate that H$_2$O$_2$ treatment induced fibrosis in myotubes, but that co-culturing with WJ-MSCs can ameliorate this degeneration. To elucidate the mechanisms involved in these changes, we next analyzed the proteins secreted from WJ-MSCs.

2.3. Identification of Proteins Secreted from WJ-MSCs in a Co-Culture System

Since WJ-MSCs are known to have a paracrine effect, we investigated proteins secreted from WJ-MSCs in a co-culture system, as described above. After co-culturing WJ-MSCs with myotubes, conditioned media were collected and concentrated 10-fold. A RayBio Biotin Label-Based Human Antibody Array 507 (RayBiotech Life, Peachtree Corners, GA, USA) was used to analyze the levels of
secreted proteins present in each of the conditioned media. We found several upregulated proteins in conditioned media of the co-culture group (Figure 3a). Among these, we focused on MMP-1, the protein most strongly upregulated in the co-culture group, as compared to WJ-MSCs alone. MMP-1 is also known to have anti-fibrotic and muscle regeneration effects. To confirm the results of the antibody array, we performed an enzyme-linked immunosorbent assay (ELISA) to measure the levels of human MMP-1 protein in each of the conditioned media. Amounts of human MMP-1 in co-culture media were increased as compared to WJ-MSC only media (Figure 3b, 3965.9 ± 0.8% of control group value).

Figure 3. Human antibody array and MMP-1 enzyme-linked immunosorbent assay (ELISA) results in conditioned media. (a) Secreted proteins present in the conditioned media were analyzed using the RayBio Biotin Label-Based Human Antibody Array 507. Compared with only Wharton’s jelly-mesenchymal stem cells (WJ-MSCs), the intensity of MMP-1, INHBA, IGFBP7, PDGFA, and THBS1 was increased in co-cultured media. MMP-1: matrix metalloproteinase-1, INHBA: inhibin, beta A, IGFBP7: insulin like growth factor binding protein 7, PDGFA: platelet derived growth factor subunit A, and THBS1: thrombospondin 1. (b) Concentration of secreted MMP-1 in each of the conditioned media was measured by using a human MMP-1 ELISA kit. A four-fold increase was observed in the co-cultured media as compared to the WJ-MSC-only media. Data are expressed as mean ± SEM (n = 5, **p < 0.01).

2.4. Human Recombinant MMP-1 Protein Has Protective Effects in an In-Vitro H2O2-Induced Fibrosis Model

MMP-1 is known to have anti-fibrotic effects, but it has not been confirmed whether MMP-1 is effective in an H2O2-induced fibrosis model. Therefore, to verify the effect of MMP-1 protein on H2O2-induced fibrosis, we added human recombinant MMP-1 protein to myotubes treated with H2O2 and demonstrated that MMP-1 treatment alleviated H2O2-induced fibrosis (Figure 4a). We also confirmed the alleviating effect of MMP-1 on fibrosis by using Sirius red staining. Collagen deposition was decreased in myotubes and was treated with MMP-1 (Figure 4b, H2O2: 133 ± 5% of control group value, +MMP-1: 105 ± 8% of control group value). Furthermore, the relative protein expression level of fibronectin was decreased (Figure 4c,d, H2O2: 149 ± 10% of control group value, +MMP-1: 119 ± 9% of control group value), and that of MHC was increased (Figure 4c,e, H2O2: 56 ± 4% of control group value, +MMP-1: 80 ± 2% of control group value). Taken together, we confirmed that WJ-MSCs secreted MMP-1 protein in co-culture systems and that this protein has an alleviating effect on H2O2-induced fibrosis.
Figure 4. MMP-1 treatment is effective in an in-vitro H2O2-induced fibrosis model. (a) After myotube differentiation, H2O2 (2 mM) was added to the growth medium, and human recombinant MMP-1 protein (5 ng/mL) was added to the cultures for 24 h. Scale bar: 100 μm. (b) The fibrosis level was assessed as a percentage of the area stained with Sirius red staining solution. Quantitative measurements were made using Image J. Data are expressed mean ± SEM (n = 3). Bars with different superscripts are significantly different (one-way ANOVA followed by Duncan multiple range test, p < 0.05). Scale bars: 100 μm. (c–e) Representative images of Western blot analysis to determine protein expression levels of fibronectin and myosin heavy chain (MHC). Beta-actin was used as a loading control. Data are expressed as mean ± SEM (n = 3). Bars with different superscripts are significantly different (one-way ANOVA followed by Duncan multiple range test, p < 0.05).

2.5. MMP-1 Is a Key Factor for the Anti-Fibrotic Effect of Human WJ-MSCs

To determine whether MMP-1 secretion was the major mechanisms involved in the anti-fibrotic effect of WJ-MSCs, MMP inhibitors (tissue inhibitor of metalloproteinase-1 [TIMP-1] and GM6001) were used to treat cells. After treatment with MMP inhibitors, WJ-MSCs were immediately co-cultured with myotubes exposed to H2O2. As observed above, WJ-MSCs attenuated fibrosis induced by H2O2 (Figure 5b, H2O2: 117 ± 3% of control group value, +WJ-MSC: 87 ± 5% of control group value). However, when TIMP-1 or GM6001 was used to treat cells, no anti-fibrotic effects were observed in either group (Figure 5b, +WJ-MSC+TIMP-1: 121 ± 3% of control group value, +WJ-MSC+GM6001: 121 ± 3% of control group value). The relative protein expression level of fibronectin was changed following a similar pattern as seen with Sirius red staining (Figure 5c,d, H2O2: 183 ± 11% of control group value, +WJ-MSC: 125 ± 7% of control group value, +WJ-MSC+TIMP-1: 225 ± 35% of control group value, +WJ-MSC+GM6001: 177 ± 13% of control group value). In contrast, the expression of MHC was increased in the WJ-MSC co-culture group as compared with the treated group. However, when MMP inhibitors were used, this effect was abrogated (Figure 5c,e, H2O2: 11 ± 4% of control group value, +WJ-MSC: 37 ± 17% of control group value, +WJ-MSC+TIMP-1: 8 ± 3% of control group value, +WJ-MSC+GM6001: 11 ± 5% of control group value). These results indicated that WJ-MSCs reduced fibrosis caused by oxidative stress mainly via the secretion of MMP-1 protein.
Figure 4. MMP-1 treatment is effective in an in-vitro H₂O₂-induced fibrosis model. (a) After myotube differentiation, H₂O₂ (2 mM) was added to the growth medium, and human recombinant MMP-1 protein (5 ng/mL) was added to the cultures for 24 h. Scale bar: 100 μm. (b) The fibrosis level was assessed as a percentage of the area stained with Sirius red staining solution. Quantitative measurements were made using Image J. Data are expressed mean ± SEM (n = 3). Bars with different superscripts are significantly different (one-way ANOVA followed by Duncan multiple range test, p < 0.05). Scale bars: 100 μm. (c–e) Representative images of Western blot analysis to determine protein expression levels of fibronectin and myosin heavy chain (MHC). Beta-actin was used as a loading control. Data are expressed as mean ± SEM (n = 3). Bars with different superscripts are significantly different (one-way ANOVA followed by Duncan multiple range test, p < 0.05).

Figure 5. MMP-1 is required for the anti-fibrotic effect of human Wharton’s jelly-mesenchymal stem cells (WJ-MSCs). (a) MMP inhibitors (TIMP-1 or GM6001) were used to block the effects of MMP-1 secreted from WJ-MSCs. Fibrosis in myotubes was induced by H₂O₂ (2 mM) and WJ-MSCs were co-cultured with the myotubes, with or without MMP inhibitors. Anti-fibrotic effects of WJ-MSCs were not observed when myotubes were treated with MMP inhibitors. Scale bars: 100 μm. TIMP-1: metallopeptidase inhibitor-1. (b) Collagen deposition was significantly decreased in the +WJ-MSC group as compared to the treated group. However, these effects were reversed in the MMP inhibitor-treated group. Quantitative measurements were made using Image J. Data are expressed as mean ± SEM (n = 3). Bars with different superscripts are significantly different (one-way ANOVA followed by Duncan multiple range test, p < 0.05). Scale bars: 100 μm. (c–e) Relative protein expression level of fibronectin and myosin heavy chain (MHC) was also observed. Fibronectin expression level was significantly decreased in the +WJ-MSC group as compared to the treated group. However, when myotubes were treated with MMP inhibitor, this level was significantly increased. In contrast, relative MHC expression level was increased in the +WJ-MSC group as compared to the treated group, but it was decreased in +WJ-MSC+TIMP-1 and +WJ-MSC+GM6001 group. Beta-actin was used as a loading control. Data are expressed as mean ± SEM (n = 3). Bars with different superscripts are significantly different (one-way ANOVA followed by Duncan multiple range test, p < 0.05).

3. Discussion

In most skeletal muscle diseases, including DMD, fibrosis is a major pathogenetic mechanism [2,28,29]. Accumulation of calcium and necrotic fibers is induced by ROS stress, causing fibrosis [30–32]. Skeletal muscle fibrosis and accumulation of calcium/necrotic fibers are increased in DMD mice [7,33–35]. Several studies have suggested potential anti-fibrotic therapy approaches for DMD [10,36,37]. As WJ-MSCs exert anti-apoptotic effects on skeletal muscle cells [27], we here investigated whether these cells could have anti-fibrotic effects, and also sought to elucidate the main paracrine factor underlying such effects. We showed that intravenous injection of WJ-MSCs into 2–5-month-old C57BL mdx mice significantly decreased fibrosis intensity and accumulation of calcium/necrotic fibers as compared to wild-type mice. We confirmed the effect of WJ-MSCs in an H₂O₂-induced fibrosis myotubes model...
and demonstrated that the paracrine factor MMP-1 is critical for these anti-fibrotic effects. For the first time, we revealed that WJ-MSCs could reduce skeletal muscle fibrosis. A recent study reported that H$_2$O$_2$, a ROS with a long half-life, diffuses both within cells and across cell membranes [38–41]. H$_2$O$_2$ can damage cellular bio-molecules, such as lipids and protein. It induces oxidative stress and results in chronic fibrosis in DMD patients [6,42,43]. Based on these characteristics, an H$_2$O$_2$-induced fibrosis model was established as an in-vitro system in this study. We revealed that myotubes exposed to H$_2$O$_2$ showed typical patterns of fibrosis, including increased expression of fibronectin. Using this in-vitro model, it was possible to study the mechanism underlying the effects of the WJ-MSCs on fibrosis.

A reduction of fibrosis was observed during fibrosis induction in myotubes co-cultured with WJ-MSCs. Furthermore, MMP-1 protein was identified as a paracrine factor through antibody array screening. In order to verify that MMP-1 was the critical factor involved in the anti-fibrotic effects of WJ-MSCs, myotubes were treated with recombinant MMP-1 protein under conditions of oxidative stress. Treatment with recombinant MMP-1 markedly reduced fibrosis in oxidative stress-induced myotubes. We further confirmed that MMP-1 is a key factor by using MMP inhibitor in our in vitro model. Similar to our results, recent studies have reported that MMP-1 has anti-fibrotic effects in a liver fibrosis model and a lacerated skeletal muscle model [44–47]. Furthermore, the increase in ECM components and upregulation of related genes in DMD patients were reported based on the analysis of differentially expressed gene profile [48]. The amount of secreted protein associated with the reported genes was found to be decreased in the co-culture conditioned media of this study, which showed that our experimental design well reflected the DMD fibrosis model. Our findings demonstrated that human WJ-MSCs play an anti-fibrotic role in skeletal muscle fibrosis via MMP-1.

We also showed increased levels of MHC in this model, but the mechanism for this observation was not identified in this study. Therefore, further study is needed to characterize the effect of MMP-1 treatment on the regenerative function of fibrotic muscle.

DMD is characterized by muscle inflammation and progressive deterioration of muscle mitochondria and function. The absence of dystrophin resulted in excessive calcium penetration into the sarcolemma (the cell membrane). Alterations in calcium and signaling pathways also cause water to enter into the mitochondria, resulting in bursting. Previous studies have documented that MSC-secreted trophic factors highly depend on external environment and status of MSC [49,50]. Some pro-inflammatory cytokines, such as IL-6, TNF-α, can induce MSC transfer of mitochondria to rescue injured cells including retinal cells, cardiomyocytes, and airway epithelia cells [51–53]. It appears a pro-inflammatory environment can enhance MSC-mitochondrial transfer and MSC mitochondrial transfer to T cells can in turn educate immune cells (CD4 T cells, i.e.) [54]. In this connection, MSC paracrine functions and mitochondrial transfer capacity are interactive and linked together to promote tissue regeneration.

It is well known that MSCs of different origins display distinct potential of cell proliferation and survival capacity. For example, MSCs from birth-associated tissues, preferably parts of the placenta and Wharton’s jelly, and pluripotent stem cell-derived MSCs, are highly proliferative and survive longer than adult tissues derived MSCs after transplantation [55–58].

Taken together, our study suggested that reduction of fibrosis by WJ-MSCs could be a novel treatment strategy for DMD.

4. Materials and Methods

4.1. Ethics Statement

This study was approved by the Institutional Animal Care and Use Committee of the Samsung Biomedical Research Institute (SBRI) at Samsung Medical Center. The SBRI is an accredited facility of the Association for Assessment and Accreditation of Laboratory Animal Care International, and abides by the Institute of Laboratory Animal Resources guidelines. In accordance with the guidelines approved
by the institutional review board of Samsung Medical Center, umbilical cords were collected with informed consent from pregnant mothers (IRB#2016-07-102).

4.2. Cell Culture

Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) were cultured according to the standard operating procedures of the Good Manufacturing Practice facility at ENCell Co. Ltd. (Seoul, Korea).

The mouse myoblast cell line, C2C12 (ATCC CRL-1772, American Type Culture Collection, Rockville, MD, USA) was cultured in Dulbecco’s Modified Eagle’s medium (Biowest S.A.S, Nuaillé, France) supplemented with 10% fetal bovine serum (Gibco BRL, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco BRL, Carlsbad, CA, USA) in 5% CO₂ at 37 °C. When myoblasts reached about 80–90% confluence, the culture medium was replaced with a myotube differentiation medium supplemented with 5% horse serum (Gibco BRL, Carlsbad, CA, USA) for 5 days.

After differentiation, 2 mM hydrogen peroxide (H₂O₂) (Sigma, St. Louis, MO, USA) was added to the growth medium for 24 h. For co-culture experiments, Transwell inserts were placed on the upper side of the myotubes, and WJ-MSCs (1 × 10⁵ cells) were seeded into the Transwell insert (pore size 1 µm, BD Biosciences, Franklin Lakes, NJ, USA) for 24 h under serum-free conditions. The myotubes were treated with or without human recombinant MMP-1 (5 ng/mL) (Sigma, St. Louis, MO, USA) for 24 h in serum-free medium. To determine whether the effect of WJ-MSCs on fibrosis is MMP-1-dependent, human recombinant metalloproteinase inhibitor-1 (TIMP-1) (100 ng/mL) or GM6001 (50 µM) (R&D Systems, Minneapolis, MN, USA), as an MMP inhibitor was used in WJ-MSC co-culture.

4.3. MMP Inhibitors Application

To determine whether the effect of WJ-MSCs on fibrosis is MMP-1-dependent, human recombinant metalloproteinase inhibitor-1 (TIMP-1) (100 ng/mL) or GM6001 (50 µM) (R&D Systems, Minneapolis, MN, USA), as an MMP inhibitor was used. After treatment with H₂O₂ for 24 h, WJ-MSCs were co-cultured with or without MMP inhibitors for 24 h in serum-free medium.

4.4. MSCs Administration

Mdx (C57BL/10ScSn-Dmdmdx/J [mdx] (JAX#001801)) and wild-type (C57BL/10ScSnJ (JAX#000476)) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA), and the offspring of the mice were bred and maintained according to the protocols recommended by the Jackson Laboratory.

Two- to five-month-old mdx mice were placed in a restraining device and injected with a total of 1 × 10⁵ WJ-MSCs (suspended in 100 µL of phosphate buffered saline) through the lateral tail vein. Mice were sacrificed using isoprene 7 days after administration.

4.5. Protein Extraction and Immunoblotting

For total protein extraction, myotubes were scraped from culture dishes and lysed in ice-cold lysis buffer containing RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mmol/L NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, 1% NP-40), urea buffer (9.8 mol/l urea, 4% CHAPS, 130 mmol/L dithiothreitol, 40 mmol/L Tris-HCl [pH 8.8], 0.1% SDS), 1 mmol/L ethylenediaminetetraacetate, and a protease/phosphatase inhibitor cocktail. Protein quantification was performed using the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Equivalent amounts of protein were loaded into SDS-polyacrylamide gels, separated, and blotted onto a PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA). After being blocked with 5% skim milk or bovine serum albumin (BSA), membranes were probed with a specific primary antibody, as follows: anti-fibronectin (ab2413, Abcam, Cambridge, UK), anti-myosin heavy chain (MAB4470, R&D Systems, Minneapolis, MN, USA), or anti-beta actin (sc-47778, Santa Cruz Biotechnology, Dallas, TX, USA). After washing with TBS-T, membranes were incubated with horseradish peroxidase-linked secondary antibody and developed using an enhanced chemiluminescence solution (Bio-Rad Laboratories, Hercules, CA, USA). The band intensities were quantified using ImageLab software (Bio-Rad Laboratories, Hercules, CA, USA).
4.6. Antibody Arrays and Enzyme-Linked Immunosorbent Assay

Proteins secreted in the conditioned media were analyzed using RayBio Biotin Label-Based Human Antibody Array 507 (#AAH-BLG-1-2, RayBiotech Life, Peachtree Corners, GA, USA). All slides were scanned using a GenePix 4100A scanner and analyzed using GenePix Pro 7.0 software (Molecular Devices, San Jose, CA, USA). All data were normalized using internal controls. To determine the concentration of MMP-1 protein secreted in conditioned media, an enzyme-linked immunosorbent assay (#ELH-MMP1-1, RayBiotech Life, Peachtree Corners, GA, USA) was performed according to the recommended protocol.

4.7. Histological Analysis

For staining, myotubes were fixed with 4% paraformaldehyde after co-culturing with WJ-MSCs or treatment with MMP-1 protein. Picro-Sirius red staining (Abcam, Cambridge, UK) was performed to detect collagen deposition in each group, and the image was analyzed using light microscopy, with quantification using Image J (NIH, New Bethesda, MD, USA).

The gastrocnemius muscles of mice were fixed in 4% paraformaldehyde and then embedded in paraffin, sectioned at 4 µm, and stained with Sirius red staining solution or Alizarin red staining solution. Sirius red staining was used to detect fibrosis, and Alizarin red to detect large accumulations of calcium/necrotic fibers, according to standard procedures. Analysis was conducted using a ScanScope AT (Leica Microsystems, Buffalo Grove, IL, USA), and the images were quantified using Image J.

4.8. Statistical Analysis

All results were analyzed by t-tests or one-way ANOVA followed by Duncan’s multiple comparison using SPSS software (version 23.0; IBM, Armonk, NY, USA). The differences were considered statistically significant at \( p < 0.05 \), and data are expressed as mean ± SEM.

**Author Contributions:** Conceptualization, J.W.C., H.B.J. and A.C.; Funding acquisition, J.W.C.; Investigation, S.E.P. and A.C.; Project administration, A.C. and J.B.J.; Resources, S.-j.C., S.-y.O., G.H.R. and J.L.; Supervision, J.W.C. and H.B.J.; Writing—original draft, J.W.C., H.B.J., S.E.P. and A.C.; Writing—review & editing, H.B.J. and J.W.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Technology Development Program (S2644635) funded by the Ministry of SMEs and Startups (MSS, Korea). The study was also supported by grants awarded by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) (HI14C3484), and funded by the Ministry of Health & Welfare, Republic of Korea. This study was also supported by National Research Foundation of Korea grants (2017R1D1A1B03028083 to H.B.J.).

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Abbreviations**

- BSA: bovine serum albumin
- DMD: Duchenne muscular dystrophy
- ECM: extracellular matrix
- ELISA: enzyme-linked immunosorbent assay
- H\(_2\)O\(_2\): hydrogen peroxide
- MHC: myosin heavy chain
- MMP-1: matrix metalloproteinase-1
- MSCs: mesenchymal stem cells
- PBS: phosphate-buffered saline
- ROS: reactive oxygen species
- SBRI: Samsung Biomedical Research Institute
- TIMP-1: tissue inhibitor of metallopeptidase-1
- WJ: Wharton’s Jelly
Appendix A

Figure A1. The effect of hydrogen peroxide on fibrosis phenotype of differentiated myotubes. (a) After myotube differentiation, various concentration of hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}) were treated to myotube for 24 h. Scale bar: 100 μm. (b) The result of Sirius red staining was quantified using Image J. Data are expressed mean ± SEM (n = 4). Bars with different superscripts are significantly different (one-way ANOVA followed by Duncan multiple range test, p < 0.05). Scale bars: 100 μm.

Figure A2. The effect of hydrogen peroxide on cell viability of differentiated myotubes. (a) The cell viability of myotube with or without hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}, 2 mM) was measured using Cell counting kit-8 (Dojindo, Rockville, MD, USA). Treatment of 2 mM H\textsubscript{2}O\textsubscript{2} did not induce cell death of myotubes. (b) Representative images of Western blot analysis to determine protein expression levels of Cleaved PARP and Annexin V. Beta-actin was used as a loading control. Data are expressed as mean ± SEM.

References

1. Serrano, A.L.; Munoz-Canoves, P. Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res. 2010, 316, 3050–3058. [CrossRef] [PubMed]

2. Klingler, W.; Jurkat-Rott, K.; Lehmann-Horn, F.; Schleip, R. The role of fibrosis in Duchenne muscular dystrophy. Acta Myol. 2012, 31, 184–195. [PubMed]

3. Pardali, E.; Sanchez-Duffhues, G.; Gomez-Puerto, M.C.; Ten Dijke, P. TGF-beta-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. Int. J. Mol. Sci. 2017, 18, 2157. [CrossRef] [PubMed]
4. Mahdy, M.A.A. Skeletal muscle fibrosis: An overview. *Cell Tissue Res.* 2019, 375, 575–588. [CrossRef] [PubMed]

5. Cholok, D.; Lee, E.; Lisiecki, J.; Agarwal, S.; Loder, S.; Ranganathan, K.; Qureshi, A.T.; Davis, T.A.; Levi, B. Traumatic muscle fibrosis: From pathway to prevention. *J. Trauma Acute Care Surg.* 2017, 82, 174–184. [CrossRef]

6. Kozakowska, M.; Pietraszek-Gremplewicz, K.; Jozkowicz, A.; Dulak, J. The role of oxidative stress in skeletal muscle injury and regeneration: Focus on antioxidant enzymes. *J. Muscle Res. Cell Motil.* 2015, 36, 377–393. [CrossRef]

7. Kharraz, Y.; Guerra, J.; Pessina, P.; Serrano, A.L.; Munoz-Canoves, P. Understanding the process of fibrosis in Duchenne muscular dystrophy. *Biomed. Res. Int.* 2014, 2014, 965631. [CrossRef]

8. Forcina, L.; Pelosi, L.; Miano, C.; Musarò, A. Insights into the Pathogenic Secondary Symptoms Caused by the Primary Loss of Dystrophin. *J. Funct. Morphol. Kinesiol.* 2017, 2, 44. [CrossRef]

9. Zhou, L.; Lu, H. Targeting fibrosis in Duchenne muscular dystrophy. *J. Neuropathol. Exp. Neurol.* 2010, 69, 771–776. [CrossRef]

10. Zhou, L.; Lu, H. Targeting fibrosis in Duchenne muscular dystrophy. *J. Neuropathol. Exp. Neurol.* 2010, 69, 771–776. [CrossRef]

11. Kim, H.J.; Seo, S.W.; Chang, J.W.; Lee, J.I.; Kim, C.H.; Chin, J.; Choi, S.J.; Kwon, H.; Yun, H.J.; Lee, J.M.; et al. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: A phase 1 clinical trial. *Alzheimers Dement.* 2015, 1, 95–102. [CrossRef]

12. Squillaro, T.; Peluso, G.; Gardarisi, U. Clinical Trials with Mesenchymal Stem Cells: An Update. *Cell Transplant.* 2016, 25, 829–848. [CrossRef] [PubMed]

13. Bartolucci, J.; Verdugo, F.J.; Gonzalez, P.L.; Larrea, R.E.; Abarzua, E.; Goset, C.; Rojo, P.; Palma, I.; Lamich, R.; Pedreros, P.A.; et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). *Circ. Res.* 2017, 121, 1192–1204. [CrossRef] [PubMed]

14. Zhang, J.; Lv, S.; Liu, X.; Song, B.; Shi, L. Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial. *Gut Liver* 2018, 12, 73–78. [CrossRef] [PubMed]

15. Caplan, A.I.; Correa, D. The MSC: An injury drugstore. *Cell Stem Cell* 2011, 9, 11–15. [CrossRef] [PubMed]

16. Lelek, J.; Zuba-Surma, E.K. Perspectives for Future Use of Extracellular Vesicles from Umbilical Cord- and Adipose Tissue-Derived Mesenchymal Stem/ Stromal Cells in Regenerative Therapies-Synthetic Review. *Int. J. Mol. Sci.* 2020, 21, 799. [CrossRef] [PubMed]

17. Gnecchi, M.; Danieli, P.; Malpasso, G.; Ciuffreda, M.C. Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair. *Methods Mol. Biol.* 2016, 1416, 123–146. [CrossRef]

18. Samsonraj, R.M.; Raghunath, M.; Nurcombe, V.; Hui, J.H.; van Wijnen, A.J.; Cool, S.M. Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. *Stem Cells Transl. Med.* 2017, 6, 2173–2185. [CrossRef]

19. Li, H.; Rong, P.; Ma, X.; Nie, W.; Chen, C.; Yang, C.; Zhang, J.; Dong, Q.; Wang, W. Paracrine effect of mesenchymal stem cell as a novel therapeutic strategy for diabetic nephropathy. *Life Sci.* 2018, 215, 113–118. [CrossRef]

20. Lee, N.K.; Na, D.L.; Chang, J.W. Killing two birds with one stone: The multifunctional roles of mesenchymal stem cells in the treatment of neurodegenerative and muscle diseases. *Histol. Histopathol.* 2018, 33, 629–638. [CrossRef]

21. Kim, D.H.; Lim, H.; Lee, D.; Choi, S.J.; Oh, W.; Yang, Y.S.; Oh, J.S.; Hwang, H.H.; Jeon, H.B. Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer’s disease model. *Sci. Rep.* 2018, 8, 1–13. [CrossRef] [PubMed]

22. Lee, N.K.; Park, S.E.; Kwon, S.J.; Shim, S.; Byeon, Y.; Kim, J.H.; Na, D.L.; Chang, J.W. Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer’s Disease Model. *Sci. Rep.* 2017, 7, 1–9. [CrossRef] [PubMed]
23. Park, S.E.; Lee, J.; Chang, E.H.; Kim, J.H.; Sung, J.H.; Na, D.L.; Chang, J.W. Activin A secreted by human mesenchymal stem cells induces neuronal development and neurite outgrowth in an in vitro model of Alzheimer’s disease: Neurogenesis induced by MSCs via activin A. Arch. Pharm. Res. 2016, 39, 1171–1179. [CrossRef]

24. Cordova, G.; Negroni, E.; Cabello-Verrugio, C.; Mouly, V.; Trollet, C. Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. Front. Genet. 2018, 9, 114. [CrossRef] [PubMed]

25. Su, W.H.; Wang, C.J.; Fu, H.C.; Sheng, C.M.; Tsai, C.C.; Cheng, J.H.; Chiang, P.C. Human Umbilical Cord Mesenchymal Stem Cells Extricate Bupivacaine-Impaired Skeletal Muscle Function via Mitigating Neutrophil-Mediated Acute Inflammation and Protecting against Fibrosis. Int. J. Mol. Sci. 2019, 20, 4312. [CrossRef]

26. Kim, D.W.; Staples, M.; Shinozuka, K.; Pantcheva, P.; Kang, S.D.; Borlongan, C.V. Wharton’s jelly-derived mesenchymal stem cells: Phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int. J. Mol. Sci. 2013, 14, 11692–11712. [CrossRef] [PubMed]

27. Kwon, S.; Ki, S.M.; Park, S.E.; Kim, M.J.; Hyung, B.; Lee, N.K.; Shim, S.; Choi, B.O.; Na, D.L.; Lee, J.E.; et al. Anti-apoptotic Effects of Human Wharton’s Jelly-derived Mesenchymal Stem Cells on Skeletal Muscle Cells Mediated via Secretion of XCL1. Mol. Ther. J. Am. Soc. Gene Ther. 2016, 24, 1550–1560. [CrossRef]

28. Pessina, P.; Cabrera, D.; Morales, M.G.; Riquelme, C.A.; Gutierrez, J.; Serrano, A.L.; Brandan, E.; Munoz-Canoves, P. Novel and optimized strategies for inducing fibrosis in vivo: Focus on Duchenne Muscular Dystrophy. Skelet. Muscle 2014, 4, 1–17. [CrossRef]

29. Sun, C.; Shen, L.; Zhang, Z.; Xie, X. Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. Genes 2020, 11, 837. [CrossRef]

30. Gillis, J.M. Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: A review. Acta Physiol. Scand. 1996, 156, 397–406. [CrossRef]

31. Law, M.L.; Cohen, H.; Martin, A.A.; Angulski, A.B.B.; Metzger, J.M. Dysregulation of Calcium Handling and Activation of Cell Death Pathways in Duchenne Muscular Dystrophy: A Review. Acta Physiol. Scand. 2016, 204, 1–17. [CrossRef] [PubMed]

32. Ameen, V.; Robson, L.G. Experimental models of duchenne muscular dystrophy: Relationship with cardiovascular disease. Open Cardiovasc. Med. J. 2010, 4, 265–277. [CrossRef] [PubMed]

33. Tutdibi, O.; Brinkmeier, H.; Rudel, R.; Fohr, K.J. Increased calcium entry into dystrophin-deficient muscle fibres of MDX and ADR-MDX mice is reduced by ion channel blockers. J. Physiol. 1999, 515 Pt 3, 859–868. [CrossRef]

34. Burr, A.R.; Molkentin, J.D. Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy. Cell Death Differ. 2015, 22, 1402–1412. [CrossRef]

35. Bozycki, L.; Łukasiewicz, K.; Matryba, P.; Pikula, S. Whole-body clearing, staining and screening of calcium deposits in the mdx mouse model of Duchenne muscular dystrophy. Skelet. Muscle 2018, 8, 21. [CrossRef] [PubMed]

36. Loboda, A.; Dulak, J. Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: Past, present, and future. Pharmacol. Rep. 2020. [CrossRef]

37. Choi, M.H.; Ow, J.R.; Yang, N.D.; Taneja, R. Oxidative Stress-Mediated Skeletal Muscle Degeneration: Molecules, Mechanisms, and Therapies. Oxid. Med. Cell. Longev. 2016, 2016, 6842568. [CrossRef] [PubMed]

38. Gough, D.R.; Cotter, T.G. Hydrogen peroxide: A Jekyll and Hyde signalling molecule. Cell Death Dis. 2011, 2, e213. [CrossRef]

39. Zang, L.; He, H.; Xu, Q.; Yu, Y.; Zheng, N.; Liu, W.; Hayashi, T.; Tashiro, S.; Onodera, S.; Ikejima, T. Reactive oxygen species H2O2 and *OH, but not O2(-) promote oridonin-induced phagocytosis of apoptotic cells by human histiocytic lymphoma U937 cells. Int. Immunopharmacol. 2013, 15, 414–423. [CrossRef]

40. Oba, T.; Koshita, M.; Yamaguchi, M. H2O2 modulates twitch tension and increases Po of Ca2+ release channel in frog skeletal muscle. Am. J. Physiol. 1996, 271, C810–C818. [CrossRef]

41. Østdal, H.; Skibsted, L.H.; Andersen, H.J. Formation of Long-Lived Protein Radicals in the Reaction between H2O2-Activated Metmyoglobin and Other Proteins. Free Radic. Biol. Med. 1997, 23, 754–761. [CrossRef]

42. Abdel, S.E.; Abdel-Meguid, I.; Korraa, S. Markers of oxidative stress and aging in Duchene muscular dystrophy patients and the possible ameliorating effect of He:Ne laser. Acta Myol. 2007, 26, 14–21. [PubMed]
43. Vielma, A.Z.; Boric, M.P.; Gonzalez, D.R. Apocynin Treatment Prevents Cardiac Connexin 43 Hemichannels Hyperactivity by Reducing Nitroso-Redox Stress in Mdx Mice. *Int. J. Mol. Sci.* 2020, 21, 5415. [CrossRef] [PubMed]

44. Giannandrea, M.; Parks, W.C. Diverse functions of matrix metalloproteinases during fibrosis. *Dis. Model. Mech.* 2014, 7, 193–203. [CrossRef] [PubMed]

45. Chen, X.; Li, Y. Role of matrix metalloproteinases in skeletal muscle: Migration, differentiation, regeneration and fibrosis. *Cell Adhes. Migr.* 2009, 3, 337–341. [CrossRef] [PubMed]

46. Wang, W.; Pan, H.; Murray, K.; Jefferson, B.S.; Li, Y. Matrix metalloproteinase-1 promotes muscle cell migration and differentiation. *Am. J. Pathol.* 2009, 174, 541–549. [CrossRef]

47. Kaar, J.L.; Li, Y.; Blair, H.C.; Asche, G.; Koepsel, R.R.; Huard, J.; Russell, A.J. Matrix metalloproteinase-1 treatment of muscle fibrosis. *Acta Biomater.* 2008, 4, 1411–1420. [CrossRef]

48. Pescatori, M.; Broccolini, A.; Minetti, C.; Bertini, E.; Bruno, C.; D’Amico, A.; Bernardini, C.; Mirabella, M.; Silvestri, G.; Giglio, V.; et al. Gene expression profiling in the early phases of DMD: A constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. *FASEB J.* 2007, 21, 1210–1226. [CrossRef]

49. Zhang, Y.; Liang, X.; Lian, Q.; Tse, H.F. Perspective and challenges of mesenchymal stem cells for cardiovascular regeneration. *Expert Rev. Cardiovasc. Ther.* 2013, 11, 505–517. [CrossRef]

50. Siu, C.W.; Liao, S.Y.; Liu, Y.; Lian, Q.; Tse, H.F. Stem cells for myocardial repair. *Thromb. Haemost.* 2010, 104, 6–12. [CrossRef]

51. Jiang, D.; Xiong, G.; Feng, H.; Zhang, Z.; Chen, P.; Yan, B.; Chen, L.; Gandhervin, K.; Ma, C.; Li, C.; et al. Donation of mitochondria by iPSC-derived mesenchymal stem cells protects retinal ganglion cells against mitochondrial complex I defect-induced degeneration. *Theranostics* 2019, 9, 2395–2410. [CrossRef] [PubMed]

52. Yao, Y.; Fan, X.L.; Jiang, D.; Zhang, Y.; Li, X.; Xu, Z.B.; Fang, S.B.; Chiu, S.; Tse, H.F.; Lian, Q.; et al. Connexin 43-Mediated Mitochondrial Transfer of iPSC-MSCs Alleviates Asthma Inflammation. *Stem Cell Rep.* 2018, 11, 1120–1135. [CrossRef] [PubMed]

53. Zhang, Y.; Ku, Z.; Jiang, D.; Liao, S.; Zhang, Z.; Yue, W.; Li, X.; Chiu, S.M.; Chai, Y.H.; et al. iPSC-MSCs with High Intrinsic MIRO1 and Sensitivity to TNF-alpha Yield Efficacious Mitochondrial Transfer to Rescue Anthracycline-Induced Cardiomyopathy. *Stem Cell Rep.* 2016, 7, 749–763. [CrossRef] [PubMed]

54. Hass, R.; Kasper, C.; Bohm, S.; Jacobs, R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. *Cell Commun. Signal.* 2011, 9, 12. [CrossRef]

55. Laroye, C.; Boufenzer, A.; Jolly, L.; Cunat, L.; Alauzet, C.; Merlin, J.L.; Yguel, C.; Bensoussan, D.; Reppel, L.; Gibot, S. Bone marrow vs Wharton’s jelly mesenchymal stem cells in experimental sepsis: A comparative study. *Stem Cell Res. Ther.* 2019, 10, 192. [CrossRef] [PubMed]

56. Zhang, J.; Chan, Y.C.; Ho, J.C.; Siu, C.W.; Lian, Q.; Tse, H.F. Regulation of cell proliferation of human induced pluripotent stem cell-derived mesenchymal stem cells via ether-a-go-go 1 (hEAG1) potassium channel. *Am. J. Physiol. Cell Physiol.* 2012, 303, C115–C125. [CrossRef] [PubMed]

57. Lian, Q.; Zhang, Y.; Zhang, J.; Zhang, H.K.; Wu, X.; Zhang, Y.; Lam, F.F.; Kang, S.; Xia, J.C.; Lai, W.H.; et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. *Circulation* 2010, 121, 1113–1123. [CrossRef] [PubMed]